Coeptis Therapeutics (COEP) Competitors $10.48 -0.55 (-5.01%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$10.51 +0.03 (+0.31%) As of 02/21/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends COEP vs. VIRI, IFRX, EPRX, SAVA, BTAI, EDIT, COYA, VIGL, DERM, and TCRXShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Virios Therapeutics (VIRI), InflaRx (IFRX), Eupraxia Pharmaceuticals (EPRX), Cassava Sciences (SAVA), BioXcel Therapeutics (BTAI), Editas Medicine (EDIT), Coya Therapeutics (COYA), Vigil Neuroscience (VIGL), Journey Medical (DERM), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry. Coeptis Therapeutics vs. Virios Therapeutics InflaRx Eupraxia Pharmaceuticals Cassava Sciences BioXcel Therapeutics Editas Medicine Coya Therapeutics Vigil Neuroscience Journey Medical TScan Therapeutics Coeptis Therapeutics (NASDAQ:COEP) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk, earnings and community ranking. Is COEP or VIRI more profitable? Virios Therapeutics' return on equity of -130.33% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -1,094.50% -219.97% Virios Therapeutics N/A -130.33%-115.00% Which has preferable valuation and earnings, COEP or VIRI? Virios Therapeutics is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$21.27M-$5.80-1.81Virios TherapeuticsN/AN/A-$5.30M-$0.27-19.85 Which has more risk & volatility, COEP or VIRI? Coeptis Therapeutics has a beta of -0.82, indicating that its share price is 182% less volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Does the MarketBeat Community prefer COEP or VIRI? Coeptis Therapeutics received 2 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 83.33% of users gave Coeptis Therapeutics an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformCoeptis TherapeuticsOutperform Votes583.33% Underperform Votes116.67%Virios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% Do analysts recommend COEP or VIRI? Virios Therapeutics has a consensus price target of $3.00, indicating a potential downside of 44.03%. Given Virios Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Virios Therapeutics is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to COEP or VIRI? In the previous week, Coeptis Therapeutics had 7 more articles in the media than Virios Therapeutics. MarketBeat recorded 7 mentions for Coeptis Therapeutics and 0 mentions for Virios Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score. Company Overall Sentiment Coeptis Therapeutics Neutral Virios Therapeutics Neutral Do insiders and institutionals hold more shares of COEP or VIRI? 13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryVirios Therapeutics beats Coeptis Therapeutics on 8 of the 14 factors compared between the two stocks. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEP vs. The Competition Export to ExcelMetricCoeptis TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.10M$3.11B$5.84B$9.14BDividend YieldN/A1.55%4.75%3.85%P/E Ratio-1.8129.6426.0419.11Price / SalesN/A329.47447.4676.36Price / CashN/A168.8738.0134.83Price / Book21.833.687.644.62Net Income-$21.27M-$71.72M$3.18B$245.85M7 Day Performance-15.85%-2.50%-2.00%-2.61%1 Month Performance-2.99%-0.32%-0.44%-2.14%1 Year Performance6.69%-12.32%16.44%12.98% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPCoeptis Therapeutics0.5506 of 5 stars$10.48-5.0%N/A+7.5%$34.10MN/A-1.812News CoverageVIRIVirios TherapeuticsN/A$6.13-8.6%$3.00-51.1%+1,411.6%$118.05MN/A-22.705IFRXInflaRx3.2978 of 5 stars$2.00-25.9%$8.00+300.0%+21.9%$117.76M$70,000.00-1.8560Gap DownHigh Trading VolumeEPRXEupraxia Pharmaceuticals3.4167 of 5 stars$3.28+1.2%$9.00+174.4%N/A$116.83MN/A-4.5629Analyst ForecastShort Interest ↓News CoverageHigh Trading VolumeSAVACassava Sciences3.7747 of 5 stars$2.42+1.7%$111.50+4,507.4%-88.5%$116.43MN/A-1.7530Gap UpBTAIBioXcel Therapeutics4.096 of 5 stars$2.31-2.9%$37.00+1,501.7%-95.8%$114.65M$1.38M-1.0790EDITEditas Medicine4.6499 of 5 stars$1.38+12.2%$7.00+407.2%-76.1%$113.92M$78.12M-0.54230Gap UpHigh Trading VolumeCOYACoya Therapeutics1.4378 of 5 stars$6.80-0.6%$16.25+139.0%-26.3%$113.63M$6M-10.466VIGLVigil Neuroscience3.1884 of 5 stars$2.76+1.8%$19.75+615.6%+0.3%$112.83MN/A-1.3440DERMJourney Medical2.5274 of 5 stars$5.24+1.0%$9.67+84.5%+38.0%$109.46M$79.18M-5.5790TCRXTScan Therapeutics2.4738 of 5 stars$2.05+0.5%$11.25+448.8%-68.8%$109.41M$9.36M-1.93100 Related Companies and Tools Related Companies Virios Therapeutics Alternatives InflaRx Alternatives Eupraxia Pharmaceuticals Alternatives Cassava Sciences Alternatives BioXcel Therapeutics Alternatives Editas Medicine Alternatives Coya Therapeutics Alternatives Vigil Neuroscience Alternatives Journey Medical Alternatives TScan Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:COEP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COEP Stock Alerts